Karl Dane Wittrup

Karl Dane Wittrup has a long and impressive work experience. Karl Dane began their career in 1999 as the C.P. Dubbs Professor at the Massachusetts Institute of Technology and later served as the Associate Director of the Koch Institute. In 2007, they co-founded Adimab, LLC, where they served as the Co-founder, Chair of the SAB and Co-founder, SAB Chair, Office of the CSO. In 2015, they joined the Scientific Advisory Board of Mersana Therapeutics, and in 2017 they joined the Scientific Advisory Board of Dragonfly Therapeutics, Inc. In 2018, they joined the Scientific Advisory Board of Werewolf Therapeutics, and in 2019 they joined the Scientific Advisory Board of Strand Therapeutics. In 2019, they co-founded Immunitas Therapeutics and in 2020 they co-founded Ankyra Therapeutics and Cullinan Amber LLC. In 2021, they co-founded 76Bio, Inc. and joined the Scientific Advisory Board.

Karl Dane Wittrup began their educational journey at The University of New Mexico, where they earned a B.S. in Chemical Engineering in 1984. Karl Dane then continued their studies at Caltech, where they completed a Ph.D. in Chemical Engineering in 1988.